Get the app
US › Healthcare

ProQR Therapeutics BV (PRQR)

US · Healthcare · Biotechnology

$1.31-9.66%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$8.9M
Revenue YoY
+133.3%
Net profit
$-8.9M
EPS
$-0.10
EPS estimate
$-0.14
Net margin
-99.6%

EPS came in at -0.10 against a street estimate of -0.14 — a beat of 28.6%.

Key statistics

Market cap
$230.0M
Forward P/E
0.0
P/B
2.63
Book value
$0.63
EPS (TTM)
$-0.45
52-week high
$3.10
52-week low
$1.33
50-day MA
$1.92
200-day MA
$1.74
Beta
0.20

Analyst view

Analysts rate ProQR Therapeutics BV a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $7.78.

Shareholding

Insiders
17.16%
Institutions
53.94%

Largest institutional holders

FundStake
Adage Capital Partners Gp LLC6.39%
Aberdeen Group PLC6.33%
Affinity Asset Advisors, LLC3.93%
Privium Fund Management B.V.3.91%
Ikarian Capital, LLC2.43%
Woodline Partners LP2.32%
Heights Capital Management Inc1.96%
Morgan Stanley - Brokerage Accounts1.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProQR Therapeutics BV — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.